EC
ZVRA icon

EntryPoint Capital’s Zevra Therapeutics ZVRA Stock Holding History

EntryPoint Capital’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$400K Sell
42,885
-9,986
-19% -$90K 0.12% 345
2025
Q4 		$474K Buy
52,871
+23,989
+83% +$227K 0.18% 187
2025
Q3 		$275K Buy
+28,882
New +$290K 0.11% 401
2025
Q2 		– Sell
-40,675
Closed -$305K – 848
2025
Q1 		$305K Buy
40,675
+14,225
+54% +$113K 0.14% 316
2024
Q4 		$221K Buy
+26,450
New +$226K 0.09% 551

Other funds holding ZVRA

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $1.6B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $488M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return